APPG hosts oral evidence sessions as part of R&D inquiry

As part of its inquiry into TB and global health research and development (R&D) the APPG hosted two oral evidence sessions in July 2020.

n

n

Speaking to expert witnesses in the UK and internationally, officers of the APPG asked questions about the future of TB and global health R&D, the UK’s research priorities moving forward, and the impact of COVID-19 on TB and global health research more broadly.

n

Over the course of two conference calls, the following witnesses were interviewed:

    n

  • Dr Nick Chapman, CEO of Policy Cures Research

    • n

  • Tabitha Ha, Advocacy Manager at STOPAIDS

    • n

  • Professor Bertie Squire, Professor of Clinical Tropical Medicine and Dean of Clinical Sciences & International Public Health and the Liverpool School of Tropical Medicine

    • n

  • Sharonann Lynch, HIV & TB Policy Advisor at Médecins sans Frontières

    • n

  • Hester Kuipers, Executive Director Europe of IAVI

    • n

  • Mike Frick, TB Project Co-Director at Treatment Action Group

    • n

  • Dr Ben Bleasdale, Senior Policy Adviser at the Wellcome Trust

    • n

n

The discussions were informed by the written evidence that had already been received from a wide variety of stakeholders. Both written and oral evidence will inform the final inquiry report, which will be launched on Parliament’s return in Autumn 2020.